title: Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
authors.forename: Tobias
authors.initials: T
authors.lastname: Herold
authors.forename: Till
authors.initials: T
authors.lastname: Seiler
authors.forename: Rupert
authors.initials: R
authors.lastname: Egensperger
authors.forename: Christoph
authors.initials: C
authors.lastname: Trumm
authors.forename: Manuela
authors.initials: M
authors.lastname: Bergmann
authors.forename: Daniel
authors.initials: D
authors.lastname: Franke
authors.forename: Friederike F H
authors.initials: FF
authors.lastname: Mumm
authors.forename: Nicole
authors.initials: N
authors.lastname: Schinwald
authors.forename: Christian
authors.initials: C
authors.lastname: Buske
authors.forename: Martin
authors.initials: M
authors.lastname: Dreyling
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003937:Diagnosis, Differential; D017809:Fatal Outcome; D006423:Hemianopsia / Q000139:chemically induced / Q000175:diagnosis; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000175:diagnosis*; D008297:Male; D000069283:Rituximab; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine